NCT05992480View on ClinicalTrials.gov

REVIVE (Response to the Ebola Virus Vaccine)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Ebola Virus Disease
Interventions
BIOLOGICAL

rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)

It is an Ebola virus vaccine

Trial Locations (1)

Unknown

Kenema Government Hospital, Kenema

All Listed Sponsors
collaborator

Kenema Government Hospital

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Tulane University

OTHER

NCT05992480 - REVIVE (Response to the Ebola Virus Vaccine) | Biotech Hunter | Biotech Hunter